Patient preferences regarding atrial fibrillation stroke prophylaxis in patients at potential risk of atrial fibrillation
- 9 March 2017
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 39 (2) , 468-472
Abstract
Background With an increasing number of options for atrial fibrillation (AF) stroke prophylaxis, there are several medication-related factors to consider. This study aimed to gain a better understanding of which preference factors influence patient decisions when selecting AF stroke prophylaxis. Objective To determine the factors that influence patient stroke prophylaxis decisions and preferred therapeutic options. Methods A questionnaire about AF stroke prophylaxis medication options was distributed to participants at risk of AF. Preferences were elicited through ranking and rating medication preference factor statements, then selecting most and least preferred treatment options. Results Reduced stroke risk and lowest risk of an intracranial haemorrhage (ICH) had the highest median preference factor ranking of 2 (IQR, 1–3.5 for stroke reduction; 2–4 for ICH risk). Reducing stroke risk, availability of a lab test to assess drug effect, and availability of an antidote were the preference factors with the highest ratings. Apixaban was the most preferred treatment option (44% blinded to drug name, 37% unblinded) while ‘No treatment’ was the least preferred option (48% blinded, 52% unblinded). Conclusions Reducing stroke risk and limiting ICH risk were the most important medication factors to participants. High inter-participant preference variability suggests the importance of including the patient in decision-making when selecting AF stroke prophylaxis.Keywords
This publication has 10 references indexed in Scilit:
- Patient values and preferences when choosing anticoagulantsPatient Preference and Adherence, 2015
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014
- Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysisCMAJ Open, 2013
- Oral Anticoagulants to Reduce the Risk of Stroke in Atrial Fibrillation: How Should a Clinician Choose?Clinical Cardiology, 2013
- Shared Decision Making: A Model for Clinical PracticeJournal of General Internal Medicine, 2012
- Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysisBMC Family Practice, 2012
- Patient Values and Preferences in Decision Making for Antithrombotic Therapy: A Systematic ReviewChest, 2012
- Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trialCanadian Medical Association Journal, 2007
- Avoidance hierarchies and preferences for anticoagulation--semi-qualitative analysis of older patients' views about stroke prevention and the use of warfarinAge and Ageing, 2004
- Epidemiologic assessment of chronic atrial fibrillation and risk of strokeNeurology, 1978